An observational study in Urinary Bladder Neoplasms, Prostatic Neoplasms and Testicular Neoplasms, sponsored by Vastra Gotaland Region. Recruiting at 2 sites in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-16.
Sponsored by Vastra Gotaland Region · Observational
Among 28 studies in Urinary Bladder Neoplasms with a site in Sweden — 7 open to participants now, 10 under way, 4 of them phase 3. Urinary Bladder Neoplasms · Sweden.
Among the 28 studies in Urinary Bladder Neoplasms with a site in Sweden, this one is the only one that started in 2022, is one of 4 observational ones, and was the 18th registered.
1,798 studies on the registry are indexed under Urinary Bladder Neoplasms; 445 are open to participants now.
Browse Urinary Bladder Neoplasms studies →7 of the 28 studies in Urinary Bladder Neoplasms with a site in Sweden are open now. Recruiting first, the newest first:
Umeå University · Sites in Sweden
Merck Sharp & Dohme LLC · Sites in Sweden, United States, Argentina and 14 more countries
Vastra Gotaland Region · Sites in Sweden
Bristol-Myers Squibb · Sites in Sweden, United States, Argentina and 19 more countries
Fore Biotherapeutics · Sites in Sweden, United States, Australia and 9 more countries
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 9 · Phase 3 10
First in 2005; this study’s year is marked. 1 started in 2022.
This study's planned enrollment of 400 is above the median of 200 across 410 observational studies indexed under Urinary Bladder Neoplasms.
Median enrollment 239 across the 24 interventional studies, 250 across the 4 observational. Of the 18 that completed or were terminated, 6 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 28 have an industry lead sponsor. The 10 most frequent:
Vastra Gotaland Region is the lead sponsor of 275 studies on the registry; 109 are open to participants now.
Vastra Gotaland Region has 2 studies filed under Urinary Bladder Neoplasms — fewer than ten, so there is no comparison to draw.
4 of the studies in Urinary Bladder Neoplasms with a site in Sweden that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05911295Phase 3Seagen, a wholly owned subsidiary of PfizerDisitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 | 2027-01-29 |
| NCT07180121Linkoeping UniversityInformation Needs and Supportive Rehabilitation Over Time in Patients Undergoing Cystectomy in Bladder Cancer | 2026-12-31 |
| NCT05264337Vastra Gotaland RegionLymphedema After Urologic Surgery | 2027-01 |
| NCT06305767Merck Sharp & Dohme LLCA Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005) | 2027-04-23 |
Among the 28 studies in Urinary Bladder Neoplasms with a site in Sweden, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Lymphedema of the extremities is common after lymph node surgery in treating several forms of cancer, e.g., breast cancer. However, very little is known of the occurrence of lymphedema of the lower extremities after urologic surgery with lymph node dissection. This project aims to describe the frequency and grade of lymphedema arising after urologic surgery, using the Lymphedema Quality of Life Questionnaire (LymQOL), Delfin MoistureMeter D, and lower limb volume measurements.
All patients undergoing urologic surgery that includes lymph node dissection
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients undergoing radical cystectomy with pelvic lymph node dissection for urinary bladder cancer
Other: Self-reported lymphedema · Other: Dielectric constant ratio · Other: Limb volume
Patients undergoing radical prostatectomy with pelvic lymph node dissection for prostate cancer
Other: Self-reported lymphedema
Patients undergoing retroperitoneal lymph node dissection for testicular cancer
Other: Self-reported lymphedema
Patients undergoing other urologic surgery with lymph node dissection of inguinal, iliacal or retroperitoneal lymph nodes
Other: Self-reported lymphedema
Lymphedema as reported by LymQOL questionnaire.
Measurement of percentage tissue water content of lower extremities by dielectric constant ratio measured by MoistureMeter D.
Measurement of lymphedema by limb volume of lower extremities by multiple measurements of circumference.
Number of patients with self-reported lymphedema at 12 months
Frequency and grade of self-reported swelling of the lower extremities as graded by LymQOL questionnaire
Time frame: 12 months after surgery
Number of patients with self-reported lymphedema at 24 months
Frequency and grade of self-reported swelling of the lower extremities as graded by LymQOL questionnaire
Time frame: 24 months after surgery
Change in tissue water content measured by MoistureMeterD Compact at 12 months
Percent tissue water content calculated from the dielectric constant as measured by MoistureMeterD Compact
Time frame: 12 months after surgery
Change in tissue water content measured by MoistureMeterD Compact at 24 months
Percent tissue water content calculated from the dielectric constant as measured by MoistureMeterD Compact
Time frame: 24 months after surgery
Change in lower limb volume calculated by measuring the circumference of the lower extremities at 12 months
Time frame: 12 months after surgery
Change in lower limb volume calculated by measuring the circumference of the lower extremities at 24 months
Time frame: 24 months after surgery
Number of patients with self-reported lymphedema at 1 month
Frequency and grade of self-reported swelling of the lower extremities as graded by LymQOL questionnaire
Time frame: 1 month after surgery
Number of patients with self-reported lymphedema at 3 months
Frequency and grade of self-reported swelling of the lower extremities as graded by LymQOL questionnaire
Time frame: 3 months after surgery
Number of patients with self-reported lymphedema at 6 months
Frequency and grade of self-reported swelling of the lower extremities as graded by LymQOL questionnaire
Time frame: 6 months after surgery
Change in tissue water content measured by MoistureMeterD Compact at 1 month
Percent tissue water content calculated from the dielectric constant as measured by MoistureMeterD Compact
Time frame: 1 month after surgery
Change in tissue water content measured by MoistureMeterD Compact at 3 months
Percent tissue water content calculated from the dielectric constant as measured by MoistureMeterD Compact
Time frame: 3 months after surgery
Change in tissue water content measured by MoistureMeterD Compact at 6 months
Percent tissue water content calculated from the dielectric constant as measured by MoistureMeterD Compact
Time frame: 6 months after surgery
Change in lower limb volume calculated by measuring the circumference of the lower extremities at 1 month
Measurements of circumference every 6 cm along the lower limbs.
Time frame: 1 month after surgery
Change in lower limb volume calculated by measuring the circumference of the lower extremities at 3 month
Measurements of circumference every 6 cm along the lower limbs.
Time frame: 3 month after surgery
Change in lower limb volume calculated by measuring the circumference of the lower extremities at 6 month
Measurements of circumference every 6 cm along the lower limbs.
Time frame: 6 month after surgery
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2022 (actual). Primary completion is estimated for Jan 2027, 58 months after the start.
Of 167 non-industry observational studies under Urinary Bladder Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 30. This study's planned 58 months is close to that.
Counting every sponsor, half of 202 studies reached it within 60 months; a quarter within 32.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.